结核病与肺部健康杂志 ›› 2014, Vol. 3 ›› Issue (4): 257-260.doi: 10.3969/j.issn.2095-3755.2014.04.010

• 论著 • 上一篇    下一篇

新密市结核病辅助用药纳入新型农村合作医疗补偿的效果分析

段海霞,何保安,靳晓伟,岗铸锋,魏晓慧,靳鸿建,何世德,刘元森   

  1. 452370 河南省新密市结核病防治所(段海霞、靳晓伟、岗铸锋、魏晓慧、靳鸿建、何世德、刘元森);河南省胸科医院药械科(何保安)
  • 收稿日期:2014-09-16 出版日期:2014-06-30 发布日期:2014-06-30
  • 通信作者: 靳鸿建,Email:xmjfs18@126.com

Effect analysis of compensation policy on TB auxiliary drug included in new rural cooperative medical scheme in Xinmi city

DUAN Hai-xia*, HE Bao-an, JIN Xiao-wei, GANG Zhu-feng, WEI Xiao-hui, JIN Hong-jian, HE Shi-de, LIU Yuan-sen   

  1. *Xinmi City Tuberculosis Prevention and Control Institute, Xinmi City of He’nan Province, Xinmi 452370,China
  • Received:2014-09-16 Online:2014-06-30 Published:2014-06-30
  • Contact: JIN Hong-jian, Email:xmjfs18@126.com

摘要: 目的 探讨肺结核患者门诊辅助用药纳入新型农村合作医疗(简称“新农合”)补偿的实施效果。方法 自2008年6月1日起,参加新农合的肺结核患者(2008年6月至2014年6月一共有3326例)除国家免费外的门诊辅助用药费用由统筹基金支付40%(2011年起提高到60%,2014年起提高到70%),个人负担60%(2011年起下降到40%,2014年起下降到30%),每人每年最高补偿限额600元(2011年起提高到1200元,2014年起提高到2000元)。结果 新农合补偿实施6年来,已为参加新农合的3018例肺结核患者报销门诊辅助用药费1 865 461.50元,人均补偿618.11元。人均补偿金额随补偿比例的提高和封顶线的提高而增加,补偿人数占参加新农合肺结核患者的90.7%(3018/3326),另外9.3%的肺结核患者因没有合并症、病情较轻不需要应用辅助药物而没有进行补偿。结论 新密市将肺结核患者门诊辅助用药纳入新农合补偿范围方法适当,效果明显。

Abstract: Objective To explore the compensation policy effect of TB auxiliary drug included in new rural cooperative medical scheme(NCMS) in Xinmi city.Methods In addition to the free policy, since June 1, 2008, NCMS compensated 40% (increased to 60% in 2011, to 70% in 2014)of the TB auxiliary drugs for pulmonary tuberculosis patients participating the NCMS(From Jun.2008 to Jun.2014, a total of 3326 patients participated the NCMS).The annually supreme compensation limits per person was 600 Yuan (increased to 1200 Yuan in 2011, increased to 2000 Yuan in 2014).Results After 6 years of implementation, the compensation policy has reimbursed a total of 1 865 461.50 Yuan RMB for 3018 cases of tuberculosis patients participated in NCMS, with an average of 618.11 Yuan per patient. The per capita amount of compensation increases with the proportion of total amount to be reimbursed and the capping lines, the number of people received compensation accounted for 90.7%(3018/3326)of tuberculosis patients participating NCSM. Another 9.3% of tuberculosis patients did not receive the compensation due to no complications and no need for auxiliary drug.Conclusion The compensation method for TB auxiliary drug is appropriate, and achieved obvious effect.